New targets and approaches in osteosarcoma

Jonathan Gill, Manpreet K. Ahluwalia, David Geller, Richard Gorlick

Research output: Contribution to journalReview article

169 Scopus citations

Abstract

Osteosarcoma is the most common primary tumor of bone. Approximately 2/3 of patients who present with localized osteosarcoma can be expected to be cured of their disease with surgery and routine chemotherapy. Only 1/3 of patients with metastases detectable at presentation will be cured. These survival trends have stagnated over the past 20 years using conventional chemotherapy. New agents need to be rationally investigated to strive for improvement in the survival of patients diagnosed with osteosarcoma. This manuscript will review the rationale for conventional chemotherapy used in the treatment of osteosarcoma, as well as agents in varying stages of development that may have promise for treatment in the future.

Original languageEnglish (US)
Pages (from-to)89-99
Number of pages11
JournalPharmacology and Therapeutics
Volume137
Issue number1
DOIs
StatePublished - Jan 2013

    Fingerprint

Keywords

  • Chemotherapy
  • Novel agents
  • Osteosarcoma
  • Review

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this